Aladdin

Mitazalimab (anti-CD40) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab (anti-CD40) activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab (anti-CD40)

Mitazalimab (anti-CD40) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab (anti-CD40) activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab (anti-CD40)

Mitazalimab (anti-CD40) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab (anti-CD40) activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab (anti-CD40)

Mitazalimab (anti-CD40) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab (anti-CD40) activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab (anti-CD40)

Gatipotuzumab (anti-MUC1) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab (anti-MUC1) reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC).Purity≥95%

Gatipotuzumab (anti-MUC1) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab (anti-MUC1) reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC).Purity≥95%

Gatipotuzumab (anti-MUC1) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab (anti-MUC1) reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC).Purity≥95%

Gatipotuzumab (anti-MUC1) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab (anti-MUC1) reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC).Purity≥95%

Marstacimab (anti-TFPI) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab (anti-TFPI) can be used for the research of hemophilia.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin Level&lt: 1.0EU/mg.

Marstacimab (anti-TFPI) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab (anti-TFPI) can be used for the research of hemophilia.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin Level&lt: 1.0EU/mg.

Marstacimab (anti-TFPI) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab (anti-TFPI) can be used for the research of hemophilia.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin Level&lt: 1.0EU/mg.

Marstacimab (anti-TFPI) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab (anti-TFPI) can be used for the research of hemophilia.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin Level&lt: 1.0EU/mg.